Show simple item record

dc.contributor.author杨善民
dc.contributor.author陈福
dc.contributor.author郑耘
dc.contributor.author王光华
dc.contributor.author曹苏伟
dc.contributor.author陈炳煌
dc.date.accessioned2016-05-17T07:20:46Z
dc.date.available2016-05-17T07:20:46Z
dc.date.issued1999
dc.identifier.citation癌症,1999,(3):57-60
dc.identifier.issn1000-467X
dc.identifier.otherAIZH903.017
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/123859
dc.description.abstract目的:研究硫代硫酸钠(STS)是否能在体内、外作为化疗药的辅药。方法:应用MTT法研究STS分别与AdM、MMC和CddP等6种抗癌单药合用时对bEl-7402和MgC80-3细胞的细胞毒性作用;应用小鼠肝癌腹水瘤(H22)模型判断STS与AdM等3种药合用时的抗癌疗效;20例人原发性肝癌病人肝动脉插管化疗(AdM、MMC和CddP)前30MIn静脉推注STS(125~25g/M2)考察STS作为化疗药辅药的作用。结果:除了CddP以外,STS(500μg/Ml)与AdM等5种抗癌单药合用时对抗癌药的抗肿瘤细胞活性无明显影响(P>005)。当不同剂量STS(350Mg/kg、35Mg/kg)分别与AdM(6Mg/kg)、MMC(14Mg/kg)和CddP(45Mg/kg)合用或仅这3种化疗药合用时,这3组腹水瘤小鼠的存活期比对照组者显著延长(P<0001),但3组之间无明显区别(P>005)。人肝癌肝动脉插管化疗时,STS与AdM、MMC和CddP抗癌药合用,肝癌治疗总有效率达60%,且可减少70%病人的恶心、呕吐等副作用。结论:在体内,低浓度的STS(125~25g/M2)可与AdM,MM?
dc.description.abstractObjective: To study whether sodium thiosulfate (STS) can be used as an adjuvant of the chemotherapy drugs. Methods: The cytotoxicity of STS combined with ADM, MMC, CDDP, 5Fu, MTX and VCR (1PPC/ml) respectively on the cells of BEL7402 and MGc803 was studied by MTT test in vitro.The ascitic hepatoma (H22) in mice were adopted to determine the anticancer effect of STS adjuvant of ADMMMC and CDDP.Being treated with STS(12525 g/m2) 30 min before drug administration,20 patients of hepatocellular carcinoma (HCC) were carried on transcatheter arterial chemoembolization with ADMMMC and CDDP to observe the adjuvant effect of STS. Results: The anticancer activity of ADM and the other agents respectively adjuvant with STS (500 g/ml) were not obviously influented (P >005), but that for CDDP was influented .It was proven that the survival time of ascitic hepatoma treated with ADM (6 mg/kg),MMC (14 mg/kg) and CDDP (45 mg/kg) alone or three drugs in addition to STS (350 mg/kg,35 mg/kg) respectively was not significantly different (P >005).The survival time of each groups was significantly longer than that of control group (P< 0001).It have also been proven that STS adjuvant of ADM, MMC and CDDP was not decreased the chemotherapry effect (RR=60%) by transcatheter arterial chemoembolization in HCC, simultaneously it alleviated the nausea and vomiting in 70%patients. Conclusion: The study provides evidence that in vivo, STS (12525 g/m2) can be used as an adjuvant of chemotherapy drugs,such as ADM,MMC, including CDDP, and so on , for decreasing nausea and vomiting effects, espacially for transcatheter chemotherapy .
dc.description.sponsorship福建省“八五”肝癌攻关课题
dc.language.isozh_CN
dc.subject肿瘤
dc.subject硫代硫酸钠
dc.subject经皮导管化疗
dc.subject药效学
dc.subjectMTT法
dc.subjectTumor
dc.subjectSodium thiosulfate
dc.subjectTranscatheter chemotherapy
dc.subjectAdjuvant
dc.subjectPharmacodynamic
dc.subjectMTT method
dc.title硫代硫酸钠在体内、外辅佐抗癌药药效学初步研究
dc.title.alternativePreliminary pharmacodynamic study of STS as an adjuvant ofthe chemotherapy drugs in Vitro and in Vivo
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record